The Opportunity
$5.6 Trillion
The global cost of mental health disorders creates an unprecedented market opportunity for effective, transformational treatment solutions.
280M+
Depression Sufferers
People globally affected by depression
301M
Anxiety Disorders
Living with anxiety worldwide
35M
Substance Use Disorders
Struggling with addiction
1 in 5
Adults Affected
Experience mental illness annually
The Crisis
Traditional Treatment is Failing
Despite billions spent annually on mental health treatment, outcomes remain poor. The system is designed for chronic management, not lasting healing.
of addicts relapse within the first year
of depression patients don't respond to medication
of PTSD patients show no improvement with CBT
spent annually on mental health in the US alone
$5.6T
Annual Cost
Global economic burden
15%
Success Rate
Traditional addiction treatment
6.7%
Market Growth
Mental health services CAGR
$10.75B
Psychedelic Market
Projected by 2027
Emerging Solution
The Psychedelic Therapy Revolution
A new paradigm in mental health treatment is emerging, backed by rigorous science and regulatory progress.
Clinical Efficacy
- 67% remission rate for treatment-resistant depression (psilocybin)
- 83% reduction in PTSD symptoms (MDMA-assisted therapy)
- 60-80% addiction interruption rate (ibogaine)
Regulatory Progress
- FDA Breakthrough Therapy designation for psilocybin
- Australia approves MDMA and psilocybin prescribing
- Mexico permits ibogaine treatment
Market Growth
- $10.75B projected market by 2027
- 15%+ CAGR for psychedelic therapy sector
- $2.4B invested in psychedelic companies (2019-2023)
Target Customer
High-Net-Worth Individuals Seeking Transformation
Our target demographic has the means to seek the best care, the sophistication to understand the science, and the desperation that comes from failed conventional treatments.
Unit Economics
Premium Pricing Power
Average Treatment Program
10-21 day programs
$35,000-$75,000
Revenue per Guest
Blended average
$48,138
Gross Margin per Guest
74% gross margin
$35,538
Customer Acquisition Cost
Blended CAC
$2,613
LTV:CAC Ratio
Strong unit economics
13.6x
Competitive Landscape
| Competitor Type | Examples | Strengths | Our Advantage |
|---|---|---|---|
| Luxury Rehab Centers | Promises, Passages Malibu | Brand recognition, insurance | Ibogaine efficacy, medical-grade protocols |
| Ayahuasca Retreats | Rhythmia, Soltara | Established, spiritual focus | Medical oversight, addiction specialization |
| Ibogaine Clinics | Beond, Clear Sky | Treatment expertise | Luxury experience, integration support |
| Bio-Optimization Centers | Bulletproof, Upgrade Labs | Wellness positioning | Combined modalities, deeper transformation |
Why Now?
We are at an inflection point where scientific validation, regulatory progress, and cultural acceptance converge to create a once-in-a-generation opportunity.
Science
Decades of research validating psychedelic therapy
Regulation
Global momentum toward legal access
Demand
Failed conventional treatments driving alternatives